Amicus Therapeutics (FOLD) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts FOLD Hot Sheet
Price: $14.49 --0%
Financial Fact:
Restructuring charges: 11K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Restructuring charges: 11K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.18), $0.04 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $86.3 million versus the consensus estimate of $83.07 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Wells Fargo starts On Holding at Overweight, sees growth reaccelerating in 2027
- Berkshire Hathaway hits 52-week high on election rally
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
